Total Funding
95
81
Total FundingGrant raised
Growth Score
1 pts
Heat Score
29 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
2708
Siren Biotechnology focuses on combining AAV gene therapy with cytokine immunotherapy to develop innovative treatments for cancer.
- Akela Kuwahara: Chief of Staff and Director of Corporate Strategy
- Nicole Paulk: CEO and Founder
About the Company
Siren Biotechnology is a biotechnology company that develops gene therapies for the treatment of solid tumors. Its research focuses on combining adeno-associated virus (AAV) gene therapy with cytokine immunotherapy into a single therapeutic approach designed to deliver localized and sustained immune activation within tumors. The company is
advancing a platform intended for use across multiple solid cancer types, including brain cancer and other difficult-to-treat malignancies, while also developing clinical-stage therapeutic candidates based on this technology. Its work includes preclinical and clinical research aimed at evaluating the safety and therapeutic potential of AAV-based immuno-gene therapies in oncology.
